Scientists said Pfizer’s RSV vaccine for older adults should be monitored for Guillain-Barre, in an article published in the New England Journal of Medicine.
The FDA sees a potential risk and has asked Pfizer to conduct a safety study on Guillain-Barre after a potential approval, which the company said it would do.
){kind=link}
){kind=link}